Share this Post!
In a two-day Cascading of FDA-related laws, rules and regulations initiated by the Policy and Planning Service (PPS), respective lawyers of the Legal Services Support Center (LSSC) discussed various laws, rules, and regulations pertinent to the Food and Drug Administration (FDA) to select personnel of each department of the FDA at Excelsior Hotel, Las Piñas City, last March 21-22, 2024.
Day 1 of the Cascading covered the foundational aspects of the FDA’s mandate, functions, and jurisdiction. Atty. Emilio L. Polig, Jr., Director III of the Legal Services Support Center, gave the FDA personnel a refresher on the Republic Act No. 9711, better known as the FDA Act of 2009. Following this, Atty. Randolph Jon P. Guerzon elaborated on Republic Act No. 11032, or the Ease of Doing Business and Efficient Government Service Delivery Act of 2018 and provided insights into FDA jurisdiction on tobacco products. Atty. Joseph James I. Jimenez then navigated through Republic Act No. 10611, the Food Safety Act of 2013. Lastly, Atty. Trixie A. Marcelo shed light on FDA registration concerning reproductive health products, referencing the legal case of Imbong vs. Ochoa (G.R. No. 204819, April 08, 2014).
On the second day of the program, Atty. Jimenez returned to the podium to discuss substantive and procedural due process, referencing the legal case of Venus Commercial Co., Inc., vs. DOH and FDA (G.R. No. 240764, November 18, 2021). As the session continued, Atty. Langley P. Gratuito then expounded on Republic Act No. 8203, the Special Law on Counterfeit Drugs. Subsequently, Atty. Trixie A. Marcelo provided insights into RA No. 9502 also known as the Universally Accessible Cheaper and Quality Medicines Act of 2008 and other related laws. The program concluded with Atty. Pamela Angeline O. Sevilla discussing Republic Act No. 10918, or the Philippine Pharmacy Act.
The cascading program facilitated an interactive platform for FDA personnel to deepen their understanding of the legal landscape underpinning the administration’s regulatory functions. This initiative underscores the FDA’s commitment to fostering continuous learning and capacity building among the agency, ensuring strong regulatory oversight and adherence to legal standards in safeguarding public health and safety.
See more:->